Trials / Conditions / ALK-positive Non-small Cell Lung Cancer

ALK-positive Non-small Cell Lung Cancer

10 registered clinical trials studyying ALK-positive Non-small Cell Lung Cancer — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC NCT07491497	TRIANA Biomedicines, Inc.	Phase 1 / Phase 2
Recruiting	Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients NCT06361589	Sichuan Cancer Hospital and Research Institute	—
Recruiting	Patient-centered, Optimal Integration of Survivorship and Palliative Care NCT04900935	Massachusetts General Hospital	N/A
Active Not Recruiting	A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal M NCT06410040	Sichuan Cancer Hospital and Research Institute	—
Recruiting	Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC NCT06092086	Guangdong Association of Clinical Trials	Phase 2
Enrolling By Invitation	ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study NCT06846736	Sheba Medical Center	—
Completed	Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Pa NCT04979988	Pfizer	—
Terminated	Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib NCT04211922	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 2
Terminated	Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma NCT02513667	University of Texas Southwestern Medical Center	Phase 2
Completed	A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Met NCT02336451	Novartis Pharmaceuticals	Phase 2